| Dokumentenidentifikation |
EP0791037 13.05.2004 |
| EP-Veröffentlichungsnummer |
0000791037 |
| Titel |
VERFAHREN ZUR STABILISIERUNG VON GELATINE-PRODUKTEN |
| Anmelder |
Warner-Lambert Co. LLC, Morris Plains, N.J., US |
| Erfinder |
CADE, Dominique, F-68000 Colmar, FR; MADIT, Nicolas, F-68100 Mulhouse, FR |
| Vertreter |
derzeit kein Vertreter bestellt |
| DE-Aktenzeichen |
69532858 |
| Vertragsstaaten |
AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE |
| Sprache des Dokument |
EN |
| EP-Anmeldetag |
31.10.1995 |
| EP-Aktenzeichen |
959396276 |
| WO-Anmeldetag |
31.10.1995 |
| PCT-Aktenzeichen |
PCT/US95/13950 |
| WO-Veröffentlichungsnummer |
0096014365 |
| WO-Veröffentlichungsdatum |
17.05.1996 |
| EP-Offenlegungsdatum |
27.08.1997 |
| EP date of grant |
07.04.2004 |
| Veröffentlichungstag im Patentblatt |
13.05.2004 |
| IPC-Hauptklasse |
C09H 5/00
|
| IPC-Nebenklasse |
A61K 9/48
|
| Beschreibung[en] |
|
FIELD OF THE INVENTION
This invention relates to a process for the enhancement of the stability
of gelatin products against higher storage temperatures, humidity and/or chemically
influenced crosslinking, as well as suitable gelatin compositions and their use
in capsule manufacturing or as coating or binding agents of tablets and casing materials.
DESCRIPTION OF THE PRIOR ART
Gelatin is widely used in the pharmaceutical industry as well as in
the health food supplement market to manufacture capsules as containers or as coating
agents for the capsules or other dosage forms, or as adjuvants or excipients in
pharmaceutical preparations like tablets. A primary objective of these dosage forms
is to have a good disintegration after being administrated in order to enable a
fast dissolution of the active substances in the appropriate digestive organ. Any
delay of the disintegration would consequently retard or even reduce the effect
of the drug. Consequently, this disintegration characteristic has to remain unchanged
over time when finished products are stored prior to use. Extensive dissolution
stability testing has been conducted to assess this stability.
Unfortunately, as has been widely described in the literature, the
risk for the gelatin product to exhibit a delay in disintegration over time is high.
A primary cause of the problem, exposure to certain aldehydes contained in the capsules
content at the initial stage or originating from the decomposition of the drug or
one of the excipients over time, has been reported in many references as a cause.
The mechanism of this chemical interaction named "crosslinking" has been well understood
as action of the aldehyde on the free amino groups of the amino acids and especially
the lysine and arginine (G. Digenis & al, to be published in J. of Pharm. Sci.).
It has also been used further in the sense that overcrosslinking of the gelatin
would make it totally insoluble and inappropriate for an enteric dosage form (G.
Gutierrez, FR-8201127).
Various patents have been published which deal with this issue. The
resistance to crosslinking by formaldehyde can be obtained by chemically modifying
the gelatin (succinylated gelatin: Toyo Jozo Co, JP 61/186315 Nippon Elanco Co,
JP-61/186314), by adding ions in it (Sanofi, FR-8708828) or silicones (R.P. Scherer,
FR-2346/69) or peptides (NITTA, EP-0 335 982).
Another procedure to protect gelatin from crosslinking is to include
in the formulation of the drug a formaldehyde scavenger (Teikoku Hormone Mfg Co,
JP-168874/1989 and Lion Corporation EP-0 242 855).
Some literature references have also reported that exposure or storage
to/under hot and humid conditions is another reason for the delay in the disintegration
of gelatin products. These conditions were reported in a temperature range of 25
to 55°C and a humidity range of 40% to 90% relative humidity. This appears to be
very important for most of the pharmaceutical applications of the gelatin where
a stability is requested for storage at 40°C with 75% RH over 3 to 6 months without
significant delay in drug dissolution.
This phenomenon was described extensively in the literature, but no
proposal has been made to explain the mechanism of the chemical reactions involved
in responsible for the poorer dissolution performance of the gelatin: H.W. GOUDA
& al., Intl. Jour. Pharmaceutics, 18, 1984, 213-215; S.A. KHALIL & al.,
Pharmazie, 29 H1, 1974, 36-37; T.C. HAHL & al., Drug Dvpt Industr. Pharmacy,
17 (7), 1991, 1001-1016; M. DEY & al., Pharmaceutical Res., 10 (9), 1993, 1295-1300;
K.S. MURPHY & al., Pharm. Techno., March, 1989, 74-82. In the state of the art,
no method is known for increasing the resistance of the gelatin to storage at hot
and humid conditions as described before.
In JP-A-53091118 a lyophilised stable antigen composition is described
which consists of a mixture of sodium chloride, magnesium chloride, calcium chloride,
gelatin, saccharose and an antigen.
SUMMARY OF THE INVENTION
The present invention relates to a process for the manufacturing of
gelatin products which have improved stability against storage under hot and humid
conditions and/or aldehydes in order to improve the dissolution of the gelatin products
comprising incorporating additives into the gelatin solution and forming the final
product as usual. A further aspect of the invention is the gelatin compositions
used for the gelatin products prepared by the process.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The gelatin to be used with the present invention may be from acid
processed pork skin known as A gelatins, from lime processed bones known as B gelatins,
from calf skin known as C gelatins, acid processed bones known as AB gelatins or
from a combination of two or more of these gelatins.
The additives are selected from the group consisting of sodium sulfate,
sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium
chloride, calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride,
iron (II) sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride,
manganese (II) sulfate, manganese (II) chloride, glutamic acid, aspartic acid, asparagine,
lysine, tryptophane, arginine, guanidine, ascorbic acid, ethylenediamine tetraacetate,
nitrilotrismethylene phosphonic acid.
The amount of additives is up to 25%, preferably 0.1 to 10% by weight
of the dry gelatin. Each additive can be added alone or in combination with one
or more additive.
Two types of storage conditions were studied:
- 1) Hot and humid conditions: temperature varied between 20 and 55°C and humidity
between 40% and 95% RH.
- 2) Formaldehyde:
- a. Capsules were filled with lactose contaminated by formaldehyde with levels
varying between 0-200 ppm, preferably between 1 and 60 ppm. These capsules were
either stored in closed bottles at 50°C up to 2 months or in the open at hot and
humid conditions up to 6 months.
- b. Gelatin films were stored in lactose powder contaminated by formaldehyde
with level between 0 and 200 ppm, preferably between 1 and 50 ppm. Films are dipped
in the contaminated lactose powder in a closed plastic box and kept at 50°C up to
1 month.
Dissolution measurements:
The dissolution measurements were made with the apparatus described
in USP XXII, method II (paddle 50 rpm). The medium was demineralized water at 37°C
± 0.5°C and two procedures were used one for the capsules and one for the gelatin
films. The samples are added in the media in a special sinker which prevents them
from floating.
1. Capsule dissolution:
The capsules are previously stored under one or both of the storage
conditions described before. The capsules were filled with Acetaminophen and dissolved
in water at 37°C under agitation (paddle 50 rpm). The percentage of dissolved Acetaminophen
is determined by UV spectrophotometry at 300 nm. The required level of dissolved
Acetaminophen is higher than 80% at 45 min.
2. Gelatin film dissolution
Films of gelatin are casted on glass plates. These films are stored
at one or both of the conditions described before. The films are then added in demineralized
water at 37°C under agitation (paddle 50 rpm) and the percentage of dissolution
is determined by UV spectrophotometry at 217 nm. Uncrosslinked films have a dissolution
of more than 90% at 6 min.
The following examples will demonstrate how the addition of inventive
compounds increases the resistance of gelatins to crosslinking by hot and humid
storage and/or formaldehyde.
Example 1:
The effect of addition of nitrilotrismethylene phosphonic acid (AMP,
Masquol® P320) on the dissolution of gelatin films stored in presence of formaldehyde
is studied. The films were prepared by casting a gelatin solution (30% w/w water)
containing Masquol® P320 (1% w/w gelatin on glass plate and drying at room conditions
for 24 hours.
The dissolution samples were then prepared and stored dipped in formaldehyde
contaminated lactose in a closed plastic box for 1 week at 50°C prior to dissolution
measurements.
The dissolution results are shown in the following table 2.
Gelatin
AMP
Dissolution
3 min
6 min
9 min
12 min
15 min
A 240
0%
0%
3%
10%
16%
21%
1%
3%
15%
26%
41%
52%
B 200
0%
8%
42%
70%
84%
87%
1%
8%
77%
89%
93%
94%
Here the beneficial effect of the addition of an additive, Masquol®
P320, on the resistance of gelatin films to formaldehyde crosslinking is clearly
demonstrated.
Effectively, a significant increase in the dissolution of gelatin
films was observed for both A 240 films (+150% at 15 min) and B 200 films (+85%
at 6 min).
Example 2:
Gelatin films with amino acids as additives were prepared and stored
at hot and humid conditions prior to dissolution measurements. Gelatin films were
casted from 30% w/w solution containing either 1% Tryptophan or 1% Glutamic acid.
Gelatin films of A 240 and of B 200 were prepared. Films were dried at room conditions
for 24 hours prior to sample preparation. The samples were stored at 50°C and 80%
RH for 3 (A240) or 4 months (B 200) prior to dissolution measurements. The results
are shown in table 3 in comparison with gelatin without additives stored at room
temperature (Ref.).
(Storage 50°C/80% RH for 3 (A 240) and 4 months (B 200)
Gelatine
Additive
Dissolution (%) after minutes
3
6
9
12
15
A 240
0%
6%
8%
14%
36%
67%
1% Glu
6%
50%
92%
99%
100%
1% Trp
10%
87%
97%
99%
100%
B 200
0%
3%
76%
92%
98%
98%
1% Glu
54%
92%
97%
99%
100%
1% Trp
59%
97%
100%
100%
100%
A 240
0% Ref.
72%
96%
99%
100%
100%
B 200
0% Ref.
96%
100%
100%
100%
100%
The dissolution results, compared with reference tests, demonstrate
that the addition of amino acids, specifically Glutamic acid and Tryptophan at 1%
level (in respect of dry gelatin) increases the dissolution of gelatin films especially
at 3 min for B 200 and 9 min for A 240 gelatins.
In both cases, we reached the total dissolution of gelatin films (100%
dissolution) more rapidly with additives than with reference films stored at the
same conditions.
Example 3:
Gelatin films with salts or organic compounds were prepared as in
example 2. The following product were added at 1% level compared to dry gelatin
weight: Masquol® P320 (AMP).
The dissolution measurements were performed as for example 3 and results
are summarized in following table 4:
Gelatine
Additive
Dissolution (%) after minutes
3
6
9
12
15
A 240
0%
6%
8%
14%
36%
67%
1% Glu
10%
92%
99%
100%
100%
1% AMP
94%
97%
100%
100%
100%
B 200
0%
3%
76%
92%
98%
98%
1% AMP
77%
94%
99%
100%
100%
A 240
0% Ref.
72%
96%
99%
100%
100%
B 200
0% Ref.
96%
100%
100%
100%
100%
The addition organic compounds (Masquol® P320) increased significantly
the dissolution of gelatin films of both type A 240 and B 200.
For A 240 the 100% dissolution is obtained at about 6 min compared
to only 8% dissolution for gelatin films without additives. This result is comparable
to reference films (Ref.) stored at normal conditions. The dissolution is higher
than 75% for B 200 gelatin after only 3 min (3% for B 200 films without additives).
These results are comparable to reference B 200 films (Ref.) stored at normal conditions.
As demonstrated from these examples, the incorporation of selected
additives into the gelatin films increases the resistance of gelatin films and capsules
to crosslinking in presence of aldehydes or when stored in hot and humid conditions.
Example 4:
The dissolution of capsules containing additives and filled with lactose
contaminated by formaldehyde (5ppm or 20 ppm) and stored at 50°C in closed bottles
for 1 or 2 months was studied. The results are expressed as the level of dissolution
of acetaminophen filled in the capsules and measured according to the USP XXII Method
2.
Test
Additive
Dissolution (%) after minutes
15
30
45
60
75
A
0%
12%
40
57%
71%
79%
B
0%
24%
50%
66%
78%
88%
1% (II)
39%
79%
95%
100%
100%
C
0%
43%
79%
94%
98%
99%
Test A: Storage 4 weeks at 50°C, 20 ppm formaldehyde
Test B: Storage 2 months at 50°C, 5 ppm formaldehyde
Test C: Reference storage at room conditions
Additive (II): Aspartic acid
The dissolution of capsules containing additives is better than the
reference one. This dissolution is equal to the dissolation of standard capsules
stored at room conditions.
|
| Anspruch[de] |
- Verfahren zur Herstellung von Gelatinefilmen, -kapseln, -hüllen oder -beschichtungen
mit verbesserter Stabilität zur Aufbewahrung unter heißen und feuchten Bedingungen
und/oder Aldehyden, dadurch gekennzeichnet, dass mindestens ein Zusatzstoff,
der ausgewählt ist aus der Gruppe, die im wesentlichen aus Natriumsulfat, Natriumchlorid,
Kaliumsulfat, Kaliumchlorid, Lithiumsulfat, Lithiumchlorid, Calciumsulfat, Calciumchlorid,
Magnesiumsulfat, Magnesiumchlorid, Eisen(II)-sulfat, Eisen(II)-chlorid, Eisen(III)-sulfat,
Eisen(III)-chlorid, Mangan(II)-sulfat, Mangan(II)-chlorid, Glutaminsäure, Asparaginsäure,
Asparagin, Lysin, Tryptophan, Arginin, Guanidin, Ascorbinsäure, Ethylendiamintetraacetat,
Nitrilotrismethylenphosphonsäure besteht, oder ein Gemisch derselben in die Gelatine
vor der Bildung eines Endgelatineprodukts in einer Menge von bis zu 25 % eingearbeitet
wird.
- Verfahren nach Anspruch 1, wobei der Zusatzstoff oder das Gemisch von Zusatzstoffen
in die Gelatine in einer Menge von etwa 0,1 bis etwa 10 Gew.-% der trockenen Gelatine
eingearbeitet wird.
- Zusatzstoffe enthaltende Gelatinezusammensetzung mit verbesserter Stabilität
zur Aufbewahrung unter heißen und feuchten Bedingungen und/oder Aldehyden,
die mindestens einen Zusatzstoff, der ausgewählt ist aus der Gruppe, die im wesentlichen
aus Natriumsulfat, Natriumchlorid, Kaliumsulfat, Kaliumchlorid, Lithiumsulfat, Lithiumchlorid,
Calciumsulfat, Calciumchlorid, Magnesiumsulfat, Magnesiumchlorid, Eisen(II)-sulfat,
Eisen(II)-chlorid, Eisen(III)-sulfat, Eisen(III)-chlorid, Mangan(II)-sulfat, Mangan(II)-chlorid,
Glutaminsäure, Asparaginsäure, Asparagin, Lysin, Tryptophan, Arginin, Guanidin,
Ascorbinsäure, Ethylendiamintetraacetat, Nitrilotrismethylenphosphonsäure besteht,
oder ein Gemisch derselben umfasst, mit Ausschluss von lyophilisierten Antigenzubereitungen,
die aus Natriumchlorid, Magnesiumchlorid, Calciumchlorid, Gelatine, Saccharose und
einem Antigen bestehen.
- Gelatinefilme, -kapseln, -hüllen oder -beschichtungen, die hergestellt wurden
aus Zusammensetzungen mit verbesserter Stabilität zur Aufbewahrung unter heißen
und feuchten Bedingungen und/oder Aldehyden, die mindestens einen Zusatzstoff, der
ausgewählt ist aus der Gruppe, die im wesentlichen aus Natriumsulfat, Natriumchlorid,
Kaliumsulfat, Kaliumchlorid, Lithiumsulfat, Lithiumchlorid, Calciumsulfat, Calciumchlorid,
Magnesiumsulfat, Magnesiumchlorid, Eisen(II)-sulfat, Eisen(II)-chlorid, Eisen(III)-sulfat,
Eisen(III)-chlorid, Mangan(II)-sulfat, Mangan(II)-chlorid, Glutaminsäure, Asparaginsäure,
Asparagin, Lysin, Tryptophan, Arginin, Guanidin, Ascorbinsäure, Ethylendiamintetraacetat,
Nitrilotrismethylenphosphonsäure besteht, oder ein Gemisch derselben umfassen.
- Gelatineprodukt nach Anspruch 4, wobei der Gelatinefilm, die Gelatinekapsel,
-hülle oder -beschichtung 0,1 bis 10 Gew.-% von mindestens einem Zusatzstoff aus
der Gruppe, die aus Tryptophan, Glutaminsäure oder Nitrilotrismethylenphosphonsäure
besteht, oder Gemischen derselben umfasst.
- Pharmazeutische Gelatinekapselhülle, die hergestellt wurde aus Zusammensetzungen
mit verbesserter Stabilität zur Aufbewahrung unter heißen und feuchten Bedingungen
und/oder Aldehyden, die mindestens einen Zusatzstoff, der ausgewählt ist aus der
Gruppe, die im wesentlichen aus Natriumsulfat, Natriumchlorid, Kaliumsulfat, Kaliumchlorid,
Lithiumsulfat, Lithiumchlorid, Calciumsulfat, Calciumchlorid, Magnesiumsulfat, Magnesiumchlorid,
Eisen(II)-sulfat, Eisen(II)-chlorid, Eisen(III)-sulfat, Eisen(III)-chlorid, Mangan(II)-sulfat,
Mangan(II)-chlorid, Glutaminsäure, Asparaginsäure, Asparagin, Lysin, Tryptophan,
Arginin, Guanidin, Ascorbinsäure, Ethylendiamintetraacetat, Nitrilotrismethylenphosphonsäure
besteht, oder ein Gemisch derselben umfassen.
- Pharmazeutische Gelatinekapselhülle, die 0,1 bis 10 Gew.-% von mindestens einem
Zusatzstoff der Gruppe, die im wesentlichen aus Natriumsulfat, Natriumchlorid, Kaliumsulfat,
Kaliumchlorid, Lithiumsulfat, Lithiumchlorid, Calciumsulfat, Calciumchlorid, Magnesiumsulfat,
Magnesiumchlorid, Eisen(II)-sulfat, Eisen(II)-chlorid, Eisen(III)-sulfat, Eisen(III)-chlorid,
Mangan(II)-sulfat, Mangan(II)-chlorid, Glutaminsäure, Asparaginsäure, Asparagin,
Lysin, Tryptophan, Arginin, Guanidin, Ascorbinsäure, Ethylendiamintetraacetat, Nitrilotrismethylenphosphonsäure
besteht, oder Gemischen derselben enthält.
- Pharmazeutische Gelatinekapselhülle nach Anspruch 7, die 0,1 bis 10 Gew.-% von
mindestens einem Zusatzstoff der Gruppe, die im wesentlichen aus Tryptophan, Glutaminsäure
oder Nitrilotrismethylenphosphonsäure besteht, oder Gemischen derselben enthält.
|
| Anspruch[en] |
- A process for the manufacturing of gelatin films, capsules, casings or coatings
with improved stability for storage under hot and humid conditions and/or aldehydes
characterized in that at least one additive selected from the group consisting
essentially of sodium sulfate, sodium chloride, potassium sulfate, potassium chloride,
lithium sulfate, lithium chloride, calcium sulfate, calcium chloride, magnesium
sulfate, magnesium chloride, iron (II) sulfate, iron (II) chloride, iron (III) sulfate,
iron (III) chloride, manganese (II) sulfate, manganese (II) chloride, glutamic acid,
aspartic acid, asparagine, lysine, tryptophane, arginine, guanidine, ascorbic acid,
ethylenediamine tetraacetate, nitrilotrismethylene phosphonic acid or a mixture
thereof is incorporated into the gelatin before forming a final gelatin product
in an amount of up to 25%.
- A process according to claim 1, wherein the additive or the mixture of additives
is incorporated in the gelatin in an amount of from about 0.1 to about 10% by weight
of the dry gelatin.
- A gelatin composition containing additives with improved stability for storage
under hot and humid conditions and/or aldehydes, comprising at least one additive
selected from the group consisting essentially of sodium sulfate, sodium chloride,
potassium sulfate, potassium chloride, lithium sulfate, lithium chloride, calcium
sulfate, calcium chloride, magnesium sulfate, magnesium chloride, iron (II) sulfate,
iron (II) chloride, iron (III) sulfate, iron (III) chloride, manganese (II) sulfate,
manganese (II) chloride, glutamic acid, aspartic acid, asparagine, lysine, tryptophane,
arginine, guanidine, ascorbic acid, ethylenediamine tetraacetate, nitrilotrismethylene
phosphonic acid or a mixture thereof with the exclusion of lyophilised antigen preparations
consisting of sodium chloride, magnesium chloride, calcium chloride, gelatin, saccharose
and an antigen.
- Gelatin films, capsules, casings or coatings prepared from compositions with
improved stability for storage under hot and humid conditions and/or aldehydes comprising
at least one additive selected from the group consisting essentially of sodium sulfate,
sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium
chloride, calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride,
iron (II) sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride,
manganese (II) sulfate, manganese (II) chloride, glutamic acid, aspartic acid, asparagine,
lysine, tryptophane, arginine, guanidine, ascorbic acid, ethylenediamine tetraacetate,
nitrilotrismethylene phosphonic acid or a mixture thereof.
- A gelatin product according to claim 4, wherein said gelatin film, capsule,
casing or coating comprises 0.1 to 10% by weight of at least one additive of the
group consisting of tryptophan, glutamic acid or nitrilotrismethylene phosphonic
acid or mixtures thereof.
- A pharmaceutical gelatin capsule shell prepared from compositions with improved
stability for storage under hot and humid conditions and/or aldehydes comprising
at least one additive selected from the group consisting essentially of sodium sulfate,
sodium chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium
chloride, calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride,
iron (II) sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride,
manganese (II) sulfate, manganese (II) chloride, glutamic acid, aspartic acid, asparagine,
lysine, tryptophane, arginine, guanidine, ascorbic acid, ethylenediamine tetraacetate,
nitrilotrismethylene phosphonic acid or a mixture thereof.
- A pharmaceutical gelatin capsule shell containing 0.1 to 10% by weight of at
least one additive of the group consisting essentially of sodium sulfate, sodium
chloride, potassium sulfate, potassium chloride, lithium sulfate, lithium chloride,
calcium sulfate, calcium chloride, magnesium sulfate, magnesium chloride, iron (II)
sulfate, iron (II) chloride, iron (III) sulfate, iron (III) chloride, manganese
(II) sulfate, manganese (II) chloride, glutamic acid, aspartic acid, asparagine,
lysine, tryptophane, arginine, guanidine, ascorbic acid, ethylenediamine tetraacetate,
nitrilotrismethylene phosphonic acid or a mixture thereof. urea, tryptophan, glutamic
acid or nitrilotrismethylene phosphonic acid or mixtures thereof.
- A pharmaceutical gelatin capsule shell according to claim 7 containing 0.1 to
10% by weight of at least one additive of the group consisting essentially of tryptophan,
glutamic acid or nitrilotrismethylene phosphonic acid or mixtures thereof.
|
| Anspruch[fr] |
- Procédé pour la fabrication de films, de gélules, d'enveloppes ou d'enrobages,
en gélatine à stabilité améliorée pour le stockage dans des conditions de chaleur
et d'humidité et/ou en présence d'aldéhydes, caractérisé en ce qu'au moins
un additif choisi à partir du groupe constitué essentiellement de sulfate de sodium,
de chlorure de sodium, de sulfate de potassium, de chlorure de potassium, de sulfate
de lithium, de chlorure de lithium, de sulfate de calcium, de chlorure de calcium,
de sulfate de magnésium, de chlorure de magnésium, de sulfate de fer (II), de chlorure
de fer (II), de sulfate de fer (III), de chlorure de fer (III), de sulfate de manganèse
(II), de chlorure de manganèse (II), d'acide glutamique, d'acide aspartique, d'asparagine,
de lysine, de tryptophane, d'arginine, de guanidine, d'acide ascorbique, de tétra-acétate
d'éthylène diamine, d'acide phosphonique de nitrilotrisméthylène, ou d'un mélange
de ceux-ci, est incorporé dans la gélatine avant la formation d'un produit final
en gélatine en une quantité allant jusqu'à 25%.
- Procédé selon la revendication 1, dans lequel l'additif ou le mélange d'additifs
est incorporé dans la gélatine en une quantité d'environ 0,1 à environ 10 % en masse
de la gélatine sèche.
- Composition de gélatine contenant des additifs à stabilité améliorée pour le
stockage dans des conditions de chaleur et d'humidité et/ou en présence d'aldéhydes,
comprenant au moins un additif choisi à partir du groupe constitué essentiellement
de sulfate de sodium, de chlorure de sodium, de sulfate de potassium, de chlorure
de potassium, de sulfate de lithium, de chlorure de lithium, de sulfate de calcium,
de chlorure de calcium, de sulfate de magnésium, de chlorure de magnésium, de sulfate
de fer (II), de chlorure de fer (II), de sulfate de fer (III), de chlorure de fer
(III), de sulfate de manganèse (II), de chlorure de manganèse (II), d'acide glutamique,
d'acide aspartique, d'asparagine, de lysine, de tryptophane, d'arginine, de guanidine,
d'acide ascorbique, de tétra-acétate d'éthylène diamine, d'acide phosphonique de
nitrilotrisméthylène, ou d'un mélange de ceux-ci excluant des préparations lyophilisées
d'antigènes constituées de chlorure de sodium, de chlorure de magnésium, de chlorure
de calcium, de gélatine, de saccharose et d'un antigène.
- Films, gélules, enveloppes, ou enrobages, en gélatine préparés à partir de compositions
à stabilité améliorée pour le stockage dans des conditions de chaleur et d'humidité
et/ou en présence d'aldéhydes comprenant au moins un additif choisi à partir du
groupe constitué essentiellement de sulfate de sodium, de chlorure de sodium, de
sulfate de potassium, de chlorure de potassium, de sulfate de lithium, de chlorure
de lithium, de sulfate de calcium, de chlorure de calcium, de sulfate de magnésium,
de chlorure de magnésium, de sulfate de fer (II), de chlorure de fer (II), de sulfate
de fer (III), de chlorure de fer (III), de sulfate de manganèse (II), de chlorure
de manganèse (II), d'acide glutamique, d'acide aspartique, d'asparagine, de lysine,
de tryptophane, d'arginine, de guanidine, d'acide ascorbique, de tétra-acétate d'éthylène
diamine, d'acide phosphonique de nitrilotrisméthylène, ou d'un mélange de ceux-ci.
- Produit en gélatine selon la revendication 4, dans lequel ledit film, ladite
gélule, ladite enveloppe, ou ledit enrobage, en gélatine comprend 0,1 à 10 % en
masse d'au moins un additif du groupe constitué de tryptophane, d'acide glutamique,
d'acide phosphonique de nitrilotrisméthylène, ou de mélanges de ceux-ci.
- Enveloppe pharmaceutique de gélule en gélatine préparée à partir de compositions
à stabilité améliorée pour le stockage dans des conditions de chaleur et d'humidité
et/ou en présence d'aldéhydes comprenant au moins un additif choisi à partir du
groupe constitué essentiellement de sulfate de sodium, de chlorure de sodium, de
sulfate de potassium, de chlorure de potassium, de sulfate de lithium, de chlorure
de lithium, de sulfate de calcium, de chlorure de calcium, de sulfate de magnésium,
de chlorure de magnésium, de sulfate de fer (II), de chlorure de fer (II), de sulfate
de fer (III), de chlorure de fer (III), de sulfate de manganèse (II), de chlorure
de manganèse (II), d'acide glutamique, d'acide aspartique, d'asparagine, de lysine,
de tryptophane, d'arginine, de guanidine, d'acide ascorbique, de tétra-acétate d'éthylène
diamine, d'acide phosphonique de nitrilotrisméthylène, ou d'un mélange de ceux-ci.
- Enveloppe pharmaceutique de gélule en gélatine contenant 0,1 à 10 % en masse
d'au moins un additif du groupe constitué essentiellement de sulfate de sodium,
de chlorure de sodium, de sulfate de potassium, de chlorure de potassium, de sulfate
de lithium, de chlorure de lithium, de sulfate de calcium, de chlorure de calcium,
de sulfate de magnésium, de chlorure de magnésium, de sulfate de fer (II), de chlorure
de fer (II), de sulfate de fer (III), de chlorure de fer (III), de sulfate de manganèse
(II), de chlorure de manganèse (II), d'acide glutamique, d'acide aspartique, d'asparagine,
de lysine, de tryptophane, d'arginine, de guanidine, d'acide ascorbique, de tétra-acétate
d'éthylène diamine, d'acide phosphonique de nitrilotrisméthylène, ou d'un mélange
de ceux-ci, d'urée, de tryptophane, d'acide glutamique, ou d'acide phosphonique
de nitrilotrisméthylène, ou de mélanges de ceux-ci.
- Enveloppe pharmaceutique de gélule en gélatine selon la revendication 7, contenant
0,1 à 10 % en masse d'au moins un additif du groupe constitué essentiellement de
tryptophane, d'acide glutamique, ou d'acide phosphonique de nitrilotrisméthylène,
ou de mélanges de ceux-ci.
|
|
|